Se connecter Inscription gratuite

Kazia Therapeutics Marge brute

Quel est le Marge brute de Kazia Therapeutics?

Le Marge brute de Kazia Therapeutics Limited est 100.00%

Quelle est la définition de Marge brute?



La marge brute est la différence entre le revenu et le coût des biens vendus, divisée par le revenu et exprimée en pourcentage.

Gross margin is a type of profit margin, specifically a form of profit divided by net revenue. It is generally calculated as the selling price of an item, minus the cost of goods sold (production or acquisition costs, not including indirect fixed costs like rent, or administrative costs). The purpose of margins is to give a description of the gross profit.

Marge brute des entreprises dans Health Care secteur sur ASX par rapport à Kazia Therapeutics

Que fait Kazia Therapeutics?

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

Entreprises avec marge brute similaire à Kazia Therapeutics